Imfinzi, tremelimumab combo boosts survival outcomes for NSCLC patients

13th September 2021 Uncategorised 0

AZ’s combo treatment reduced the risk of disease progression or death by 28% compared to chemotherapy alone

More: Imfinzi, tremelimumab combo boosts survival outcomes for NSCLC patients
Source: News